Published in PLoS One on December 12, 2014
Mining for Candidate Genes Related to Pancreatic Cancer Using Protein-Protein Interactions and a Shortest Path Approach. Biomed Res Int (2015) 0.77
Detecting human melanoma cell re-differentiation following BRAF or heat shock protein 90 inhibition using photoacoustic and magnetic resonance imaging. Sci Rep (2017) 0.75
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
HSP90 and the chaperoning of cancer. Nat Rev Cancer (2005) 11.98
Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol (2012) 7.39
HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol (2010) 7.16
Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer (2010) 6.81
Quantitative reverse transcription-polymerase chain reaction to study mRNA decay: comparison of endpoint and real-time methods. Anal Biochem (2000) 6.74
Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res (2008) 6.05
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med (2009) 4.68
A critical function for type I interferons in cancer immunoediting. Nat Immunol (2005) 4.14
Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science (2013) 3.91
Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol (2011) 3.66
Hsp90 chaperones protein folding in vitro. Nature (1992) 3.19
V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc Natl Acad Sci U S A (2005) 2.93
Resistance to BRAF inhibition in melanomas. N Engl J Med (2011) 2.58
The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol (1998) 2.48
HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin Cancer Res (2011) 2.43
Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. Cancer Res (2005) 2.34
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Clin Cancer Res (2008) 1.94
Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket. Curr Med Chem (2008) 1.84
Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma. Ophthalmology (2009) 1.78
4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. J Med Chem (2007) 1.67
Targeting of the protein chaperone, HSP90, by the transformation suppressing agent, radicicol. Oncogene (1998) 1.46
Characterization of celastrol to inhibit hsp90 and cdc37 interaction. J Biol Chem (2009) 1.45
Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy. Curr Opin Chem Biol (2010) 1.43
Nuclear and cytoplasmic mRNA quantification by SYBR green based real-time RT-PCR. Methods (2006) 1.37
Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS One (2014) 1.37
Role of the mitogen-activated protein kinase signaling pathway in the regulation of human melanocytic antigen expression. Mol Cancer Res (2006) 1.34
A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma. Invest New Drugs (2010) 1.30
Synthesis and biological activities of novel 17-aminogeldanamycin derivatives. Bioorg Med Chem (2004) 1.29
BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Mol Cancer Ther (2009) 1.29
New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential. Drug Resist Updat (2009) 1.27
An interaction network predicted from public data as a discovery tool: application to the Hsp90 molecular chaperone machine. PLoS One (2011) 1.27
Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer. Mol Cancer Ther (2008) 1.18
BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors. Mol Cancer Ther (2008) 1.16
Purine-scaffold Hsp90 inhibitors. Curr Top Med Chem (2009) 1.11
In vitro biological characterization of a novel, synthetic diaryl pyrazole resorcinol class of heat shock protein 90 inhibitors. Cancer Res (2007) 1.07
Gedunin, a novel hsp90 inhibitor: semisynthesis of derivatives and preliminary structure-activity relationships. J Med Chem (2008) 1.07
The heat shock protein 90-CDC37 chaperone complex is required for signaling by types I and II interferons. J Biol Chem (2005) 1.05
Phenotypic and functional effects of heat shock protein 90 inhibition on dendritic cell. J Immunol (2007) 1.00
HSP90alpha and HSP90beta isoforms selectively modulate MHC class II antigen presentation in B cells. J Immunol (2009) 0.97
Induction of "antigen silencing" in melanomas by oncostatin M: down-modulation of melanocyte antigen expression. Mol Cancer Res (2003) 0.96
Combination therapy with HSP90 inhibitor 17-DMAG reconditions the tumor microenvironment to improve recruitment of therapeutic T cells. Cancer Res (2012) 0.92
In vivo accumulation of the same anti-melanoma T cell clone in two different metastatic sites. Proc Natl Acad Sci U S A (1997) 0.90
Strategies to overcome obstacles to successful immunotherapy of melanoma. Int J Immunopathol Pharmacol (2008) 0.90
Blocking NF-κB and Akt by Hsp90 inhibition sensitizes Smac mimetic compound 3-induced extrinsic apoptosis pathway and results in synergistic cancer cell death. Apoptosis (2011) 0.88
HSP90 inhibitors induce desensitization of EGF receptor via p38 MAPK-mediated phosphorylation at Ser1046/1047 in human pancreatic cancer cells. Oncol Rep (2010) 0.87
Enhancement of human melanoma antigen expression by IFN-beta. J Immunol (2007) 0.82
Studies of the mechanism of cytolysis by tumour-infiltrating lymphocytes. Clin Exp Immunol (1999) 0.82
A novel class of specific Hsp90 small molecule inhibitors demonstrate in vitro and in vivo anti-tumor activity in human melanoma cells. Cancer Lett (2011) 0.81
Accelerated HER-2 degradation enhances ovarian tumor recognition by CTL. Implications for tumor immunogenicity. Mol Cell Biochem (2001) 0.80
Topoisomerase inhibitors modulate expression of melanocytic antigens and enhance T cell recognition of tumor cells. Cancer Immunol Immunother (2010) 0.80
CARTs on the road for myeloma. Clin Cancer Res (2014) 0.80
Hsps are up-regulated in melanoma tissue and correlate with patient clinical parameters. Cell Stress Chaperones (2012) 0.79
A screening assay to identify agents that enhance T-cell recognition of human melanomas. Assay Drug Dev Technol (2011) 0.77
Autoimmune depigmentation following sensitization to melanoma antigens. Methods Mol Med (2004) 0.77